# Ri CareSource

Patient Information				
Patient's (Child's) Name:		□M □F Date:		
Gestational Age of Birth: Weeks Days	Birth Weight:	b/kg Current Weight: Ib/kg DOB:		
Patient's Address:				
City/State/Zip:				
Phone Number: ()	Parent's Name:			
Primary Insurance:	ID #			
Secondary Insurance:		ID #		

# Synagis criteria are based on 2014 American Academy of Pediatrics Guidelines. Medical Authorization Clinical Criteria (Please check ALL that apply.)

Is this a multiple birth (twins, triplets, etc.)?

#### Pre-term birth:

 $\Box$  < 12 months of age at the beginning of the Respiratory Syncytial Virus (RSV) season

□ Born < 29 weeks, 0 days gestation

## Chronic Lung Disease of Prematurity:

#### Diagnosis/ICD-10:

- <<u>12 months of age</u> at the beginning of RSV season with chronic lung disease of prematurity defined as birth before 32 weeks, 0 days AND a requirement for > 21% oxygen for at least 28 days after birth
- <u>12-24 months of age</u> at the beginning of the RSV season with chronic lung disease of prematurity defined as birth before 32 weeks, 0 days gestation AND > 21% oxygen for at least 28 days OR after birth, member is treated with either corticosteroid or diuretic therapy within the 6-month period before the start of RSV season

(dates \_\_\_\_

(dates

- If patient is receiving medical treatment, check all that apply below and provide dates:
- Oxygen
- Corticosteroid
- - Please list drug(s): \_

#### Pulmonary/Neuromuscular Abnormalities:

Diagnosis/ICD-10:

<u>< 12 months of age</u> at the beginning of RSV season with qualifying disease that impairs the ability to swallow/cough/clear secretions from the upper airways

### Cystic Fibrosis:

Diagnosis/ICD-10:

- $\Box \leq 12$  months of age at the beginning of the RSV season with clinical evidence of CLD and/or nutritional compromise in the first year of life
- □ 12-24 months of age at the beginning of the RSV season with one of the following:
  - i) Manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life, or abnormalities on chest radiography or chest computer tomography that persist when stable)
  - ii) Weight for length less than the 10th percentile on a pediatric growth chart

#### Congenital Heart Disease:

Diagnosis/ICD-10:

- $\Box \leq 12$  months of age at the beginning of the RSV season with hemodynamically significant congenital heart disease with one or more of the following:
  - i) Acyanotic heart disease [e.g., atrial septal defect (ASD), ventricular septal defect (VSD), etc.], AND member is receiving medication to control congestive heart failure (CHF) AND will require cardiac surgical procedures
  - ii) Moderate to severe pulmonary hypertension
  - iii) Cyanotic heart disease and referred by a pediatric cardiologist [e.g., coarctation of aorta, Ebstein's anomaly, hypoplastic left heart syndrome, Tetralogy of Fallot (TOF), Total Anomalous Pulmonary Venous Connection (TAPVC), etc.]

Documented diagnosis must be confirmed by the individual's medical record and will need to be supplied with the prior authorization request. These medical records may include, but are not limited to test reports, chart notes from provider's office or hospital admission notes.

	Immunocompromised: Diagnosis/ICD-10: Diagnosis/ICD-10: Description: Description: Description: Description: ii) Concurrent chemotherapy iii) Organ transplants (cardiac, live iv) Other conditional immunocom	red profoundly immunoc er, etc.)		
	Other Conditions: Diagnosis/ICD-10: Stem cell transplant Concurrent chemotherapy Organ transplant Comments:			
Was there a hospital/NICU dos	e given? □ Yes □ No Date Administe			
Drug Claim to be Submitted by: Prescribing Physician Preferred Specialty Phane Other	Dispensing Pharmacy	Address		Drug Claim to be submitted to: Medical Benefit Pharmacy Benefi
Place of Service:	Member's Home, Administered by			
Office Contact		Phone	Fax	
City/State/Zip	DEA #	Tax ID (required)		

Authorizations are not a guarantee of payment. Authorizations are based on medical necessity and are contingent upon eligibility and benefits.

GA-P-0438d

DCH Approved: 12/27/2022